Quent Capital LLC Purchases 312 Shares of Danaher Co. (NYSE:DHR)

Quent Capital LLC raised its position in Danaher Co. (NYSE:DHR) by 13.4% during the third quarter, Holdings Channel reports. The firm owned 2,635 shares of the conglomerate’s stock after purchasing an additional 312 shares during the period. Quent Capital LLC’s holdings in Danaher were worth $731,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Tsfg LLC boosted its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Danaher during the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the second quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new stake in Danaher in the first quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. acquired a new position in Danaher in the fourth quarter valued at approximately $42,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 0.2 %

Shares of DHR stock traded down $0.49 on Friday, hitting $270.03. The stock had a trading volume of 1,132,669 shares, compared to its average volume of 2,759,666. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The business has a 50 day moving average of $271.07 and a 200 day moving average of $258.56. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The stock has a market cap of $200.01 billion, a price-to-earnings ratio of 45.77, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 EPS. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. As a group, analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on DHR shares. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Barclays lifted their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Robert W. Baird increased their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Leerink Partners boosted their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Finally, Stifel Nicolaus increased their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.